Compare PNC & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PNC | REGN |
|---|---|---|
| Founded | 1852 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.9B | 79.4B |
| IPO Year | N/A | 1991 |
| Metric | PNC | REGN |
|---|---|---|
| Price | $223.32 | $739.74 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 20 | 23 |
| Target Price | $228.74 | ★ $794.96 |
| AVG Volume (30 Days) | ★ 3.0M | 917.4K |
| Earning Date | 01-16-2026 | 01-30-2026 |
| Dividend Yield | ★ 3.05% | 0.51% |
| EPS Growth | ★ 20.86 | 8.19 |
| EPS | 16.61 | ★ 41.48 |
| Revenue | ★ $22,320,000,000.00 | $14,342,900,000.00 |
| Revenue This Year | $16.44 | $8.06 |
| Revenue Next Year | $4.74 | $10.25 |
| P/E Ratio | ★ $13.45 | $17.87 |
| Revenue Growth | ★ 7.48 | 0.99 |
| 52 Week Low | $145.12 | $476.49 |
| 52 Week High | $227.78 | $821.11 |
| Indicator | PNC | REGN |
|---|---|---|
| Relative Strength Index (RSI) | 60.47 | 44.38 |
| Support Level | $219.40 | $747.30 |
| Resistance Level | $227.78 | $776.25 |
| Average True Range (ATR) | 4.41 | 20.98 |
| MACD | -0.19 | -3.10 |
| Stochastic Oscillator | 75.51 | 24.10 |
PNC Financial is one of the three super-regional banks in the US, with around $560 billion in total assets at the end of June 30, 2025. Headquartered in Pittsburgh, Pennsylvania, PNC Financial has a coast-to-coast branch network, with a strong presence in the US Midwest and Northeast. It is currently expanding in the Southern and Western regions of the US. The bank provides a diversified set of financial services in retail banking, commercial banking, card and treasury management, asset management, and investment banking. PNC derived around 37% of revenue from fee income and 63% from net interest income in 2024.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).